[go: up one dir, main page]

MX386700B - Inhibidores de la tirosina quinasa de bruton y metodos de su uso. - Google Patents

Inhibidores de la tirosina quinasa de bruton y metodos de su uso.

Info

Publication number
MX386700B
MX386700B MX2018007084A MX2018007084A MX386700B MX 386700 B MX386700 B MX 386700B MX 2018007084 A MX2018007084 A MX 2018007084A MX 2018007084 A MX2018007084 A MX 2018007084A MX 386700 B MX386700 B MX 386700B
Authority
MX
Mexico
Prior art keywords
methods
bruton
tyrosine kinase
kinase inhibitors
compounds
Prior art date
Application number
MX2018007084A
Other languages
English (en)
Other versions
MX2018007084A (es
Inventor
Genesis M Bacani
Scott D Bembenek
Baoyu Hao
Brahmananda Ghosh
Wei Chen
Charlotte Pooley Deckhut
James P Edwards
Feihuang Zhang
Gang Li
Joseph Kent Barbay
Kevin Kreutter
Min Cai
Nidhi Arora
Mark S Tichenor
Jennifer D Venable
Jianmei Wei
John J M Wiener
Kun Xiao
Yao Wu
Yaoping Zhu
Zheng Zhang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2018007084A publication Critical patent/MX2018007084A/es
Publication of MX386700B publication Critical patent/MX386700B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/16Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente descripción se refiere a compuestos de la fórmula I y métodos para su uso y preparación, así como composiciones que comprenden compuestos de la fórmula I. (ver Fórmula).
MX2018007084A 2015-12-10 2016-12-09 Inhibidores de la tirosina quinasa de bruton y metodos de su uso. MX386700B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562265780P 2015-12-10 2015-12-10
PCT/US2016/065964 WO2017100668A1 (en) 2015-12-10 2016-12-09 Inhibitors of bruton's tyrosine kinase and methods of their use

Publications (2)

Publication Number Publication Date
MX2018007084A MX2018007084A (es) 2018-11-09
MX386700B true MX386700B (es) 2025-03-19

Family

ID=57681785

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007084A MX386700B (es) 2015-12-10 2016-12-09 Inhibidores de la tirosina quinasa de bruton y metodos de su uso.

Country Status (16)

Country Link
US (3) US10689396B2 (es)
EP (1) EP3386992B1 (es)
JP (2) JP7110097B2 (es)
KR (1) KR20180094514A (es)
CN (2) CN109071563A (es)
AR (1) AR107041A1 (es)
AU (1) AU2016366546B2 (es)
BR (1) BR112018011525B1 (es)
CA (1) CA3007993C (es)
EA (1) EA038031B1 (es)
IL (1) IL259862B (es)
JO (1) JO3793B1 (es)
MX (1) MX386700B (es)
TW (1) TWI739779B (es)
UY (1) UY37016A (es)
WO (1) WO2017100668A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3003987B2 (ja) 1996-08-20 2000-01-31 篠▲崎▼ 晴彦 合成樹脂管内に施設されるケーブルの支持装置及びそのケーブル支持具を取付ける方法
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018170220A1 (en) * 2017-03-15 2018-09-20 Janssen Sciences Ireland Uc Methods of selective aryl- and heteroaryl-nitrogen bond formation
CN110028525A (zh) * 2018-04-13 2019-07-19 太仓运通新材料科技有限公司 一种2-氟磷酰基乙酸三乙酯的合成方法
CN112513036B (zh) 2018-05-17 2024-05-24 福马治疗有限公司 用作泛素特异性肽酶30抑制剂的稠合双环化合物
ES2945834T3 (es) * 2018-10-05 2023-07-07 Forma Therapeutics Inc Pirrolinas fusionadas que actúan como inhibidores de la proteasa 30 específica de ubiquitina (USP30)
US20230030720A1 (en) 2018-12-06 2023-02-02 Daiichi Sankyo Company, Limited Cycloalkane-1,3-diamine derivative
WO2021043200A1 (zh) * 2019-09-04 2021-03-11 正大天晴药业集团股份有限公司 一种喹唑啉衍生物的制备方法及其结晶
CN111635368B (zh) * 2020-06-12 2021-06-29 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法
CN114478346A (zh) * 2021-12-31 2022-05-13 和鼎(南京)医药技术有限公司 一种制备乌帕替尼中间体的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
WO2006031929A2 (en) 2004-09-15 2006-03-23 Janssen Pharmaceutica, N.V. Thiazolopyridine kinase inhibitors
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
CN101277689B (zh) 2005-08-08 2011-01-12 詹森药业有限公司 噻唑并嘧啶类激酶抑制剂
US7427625B2 (en) 2006-02-08 2008-09-23 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
EP2365970B1 (en) 2008-11-12 2018-03-21 Gilead Connecticut, Inc. Pyridazinones and their use as btk inhibitors
US9371567B2 (en) 2010-04-19 2016-06-21 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of BTK inhibitors
FR2978441A1 (fr) 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
JP6777398B2 (ja) 2013-03-15 2020-10-28 ヤンセン ファーマシューティカ エヌ.ベー. 薬剤を調製するための方法と中間体
SI3080103T1 (sl) * 2013-12-11 2018-11-30 Biogen Ma Inc. Biarilne spojine, ki so uporabne za zdravljenje človeških bolezni na področju onkologije, nevrologije in imunologije
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
JO3794B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103060A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
CN113105475B (zh) 2022-09-09
BR112018011525A2 (pt) 2018-11-21
US20190284204A1 (en) 2019-09-19
EP3386992A1 (en) 2018-10-17
US10822348B2 (en) 2020-11-03
US10689396B2 (en) 2020-06-23
TW201734020A (zh) 2017-10-01
KR20180094514A (ko) 2018-08-23
EA038031B1 (ru) 2021-06-25
JP7110097B2 (ja) 2022-08-01
EA201891379A1 (ru) 2018-12-28
TWI739779B (zh) 2021-09-21
JP7471348B2 (ja) 2024-04-19
IL259862A (en) 2018-07-31
US20170283431A1 (en) 2017-10-05
UY37016A (es) 2017-06-30
IL259862B (en) 2022-04-01
JP2022141851A (ja) 2022-09-29
JO3793B1 (ar) 2021-01-31
BR112018011525B1 (pt) 2023-10-24
JP2018536684A (ja) 2018-12-13
MX2018007084A (es) 2018-11-09
CN109071563A (zh) 2018-12-21
CA3007993A1 (en) 2017-06-15
AU2016366546A1 (en) 2018-05-31
CN113105475A (zh) 2021-07-13
AU2016366546B2 (en) 2021-08-12
CA3007993C (en) 2024-01-16
US10800792B2 (en) 2020-10-13
WO2017100668A1 (en) 2017-06-15
AR107041A1 (es) 2018-03-14
US20190284203A1 (en) 2019-09-19
EP3386992B1 (en) 2019-11-27

Similar Documents

Publication Publication Date Title
MX386700B (es) Inhibidores de la tirosina quinasa de bruton y metodos de su uso.
MX2018007075A (es) Compuestos policiclicos como inhibidores de tirosina quinasa de bruton.
MX2020001598A (es) Inhibidores selectivos de proteína arginina metiltransferasa 5 (prmt5).
CR20190566A (es) Inhibidores de quinasay usos de los mismos
EA201492056A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
MX385082B (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
EA201892147A1 (ru) Бициклические соединения
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MY179781A (en) Biaryl inhibitors of bruton's tyrosine kinase
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
MX381487B (es) Ciertos inhibidores de la proteina quinasa.
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201991799A1 (ru) Диспергируемые в воде составы
EA201692525A1 (ru) Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов
EA201600636A1 (ru) 2-амино-6-метил-4,4а,5,6-тетрагидропирано[3,4-d][1,3]тиазин-8а(8н)-ил-1,3-тиазол-4-ил амиды
EA201691044A1 (ru) Новый октагидро-циклобута[1,2-c;3,4-c']дипиррол-2-ил
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
EA201992147A1 (ru) Ингибиторы тирозинкиназы брутона
CR20200275A (es) Hidroxiisoxazolinas y derivados de estos
EA201692289A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов